Sjögren's disease & overlap diseases
Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA+ individuals without a systemic autoimmune rheumatic disease diagnosis
Authors' conclusion
Easily performed ELISA assays for CXCL-10 and IFN-α can be used to predict ANA+ individuals at high risk of imminent symptomatic progression.
Study context
- Population
- ANA+ individuals without a SARD diagnosis, ANA- healthy controls and SARD patients160 ANA+ without SARD
- Participants
- 280 individuals
- Exposure
- Serum IFN-α and IFN-induced cytokines (CXCL-10, Galectin-9) vs IFN-induced gene expression as predictors of progression
- ANA- healthy controlsn = 50reference
- ANA+ asymptomaticn = 96
- ANA+ UCTDn = 64
- SARDn = 70
- Outcome
- Progression: new onset of SARD criteria in ANA+ individuals lacking a SARD diagnosis
- Follow-up
- 2 years
Methodological detailsbiomarker study, 2-year follow-up, IFN-induced gene expression by nanoString; cytokines by ELISA or Simoa
- Biomarker study
- 2-year follow-up
- IFN-induced gene expression by nanoString; cytokines by ELISA or Simoa
Main finding
As reported in the abstract
Prediction of progression in ANA+ individuals
Optimal combination (CXCL-10 and IFN-α by ELISA): specificity
100%
Optimal combination (CXCL-10 and IFN-α by ELISA): PPV
100%
Observational data: associations, not effects.
Further findings
Correlation with IFN-induced gene expression
- IFN-α by high-sensitivity ELISA or Simoa correlated much better with IFN-induced gene expression than CXCL-10 or Galectin-9
Original publication
Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA+ individuals without a systemic autoimmune rheumatic disease diagnosis. Arthritis Res Ther. Published 10 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →